Precision Toxicology LLC

Precision Toxicology LLC

Precision Toxicology LLC

Overview
Headquarters

4215 Sorrento Valley Boulevard,San Diego, CA 92121

Type of Company

Private

Industries

Medical Support Services
Other Business & Consulting Services

Company Description

Precision Toxicology LLC provides drug testing services. It specializes in quantitative confirmation urine drug testing designed to monitor patients on chronic opioid therapy. The firm offers NextGen precision testing, precision TBM, SOF-Adhere and oral fluid testing services. Precision Toxicology was founded by Jason Hansen and is headquartered in San Diego, CA.

Executives & Employees

Chief Executive Officer

Paths to Precision Toxicology LLC
Potential Connections via
Relationship Science
You
Precision Toxicology LLC
Recent Transactions
Details Hidden

BelHealth Investment Partners LLC purchases Precision Toxicology LLC

Investors
Details Hidden

Co-Founder at RevGen Partners, Inc.

Details Hidden

BelHealth Investment Partners focuses exclusively on investments in small-cap companies in the healthcare industry. The firm targets undervalued or undermanaged, founder-owned, public or private companies in which their operating experience and resources can drive growth and profitability. BelHealth invests primarily in low to medium technology companies in the healthcare services, healthcare information technology, marketed pharmaceutical and marketed medical products industries.BelHealth looks for companies with enterprise value up to $100 million, revenues of $10 million to $100 million, proforma operating profits near break-even up to $10 million and the potential to improve operating margins. In addition, they seek companies with long-term competitive advantages in attractive potential markets and the potential for profitable exit opportunities within 3 to 5 years. BelHealth targets early growth stage companies with recurring revenue models, low customer concentration, little or no exposure to reimbursement risk, the potential for margin expansion and low operating leverage. The firm does not consider investments in companies that have not yet generated revenue, depend heavily on government reimbursement, market commodity products/services or companies requiring significant capital investment.BelHealth typically invests $10 million to $20 million per company. Investments are generally structured as equity stakes, although BelHealth may also use other structures such as convertible debt to mitigate or minimize risks as appropriate. They may utilize securities with liquidation preferences such as preferred, participating or convertible preferred stock or equity-linked debt. BelHealth employs a limited use of leverage. The firm prefers to make control investments, either through majority ownership and/or board control. BelHealth also prefers to participate in situations in which management retains meaningful ownership and receives compensation packages that reward strong performance.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Precision Toxicology LLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Precision Toxicology LLC's profile does not indicate a business or promotional relationship of any kind between RelSci and Precision Toxicology LLC.